DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Thursday, 8 January 2015

1,1-Dimethyl-3,8-dihydro-1H-indeno[1,2-c]thiophen-3-one












1,1-Dimethyl-3,8-dihydro-1H-indeno[1,2-c]thiophen-3-one 
3,6-Di(2-pyridyl)­s­tetrazine (0.45g; 1.9 mmol) was added slowly to a stirred solution of the hydrocarbon 33 (0.30g; 1.6 mmol) and thiophosgene (0.125 ml; 1.6 mmol) in a 1:1 mixture of ethanol and chloroform (10 ml) and the resulting mixture stirred for 15 minutes. The solvent was removed and the residue partitioned between ether and water. The ethereal phase was washed with hydrochloric acid (3 x 20 ml; 0.5M) and water (2 x 10 ml), dried, and the solvent removed to yield the crude product. Purification by rapid preparative thin­layer chromatography (silica, chloroform/light petroleum 2:1) yielded a pale brown coloured oil which crystallized from ethanol. Recrystallization from ethanol afforded the product as clear, pale brown crystals (0.18g; 52%), m.p. 66-67 oC.
uv, visible spectrum: lmax 238, 243 (inf), 263 (inf), 300 (inf), nm; e 12650, 12080, 5120, 1490.
infra red spectrum: umax 1695 (s), 1315 (w), 1305 (m), 1270 (m), 1240 (m), 1200 (w), 1185 (w), 1145 (m), 1120 (m), 1080 (w), 1065 (m), 1015 (w), 870 (w), 855 (w), 835 (s), 780 (m), 760 (m), 720 (s), 690 (m) cm-1.
P.m.r. spectrum (CDCl3): d 1.82 (6H, s, methyl protons), 3.54 (2H, s, benzylic protons), 7.20-7.60 (3H, m, Hb), 7.70-7.90 (1H, m, Ha),
13C-[1H] nmr spectrum (CDCl3): d 29.12 (C9 & C10), 33.70 (C8), 55.90 (C1), 121.04 (C5), 124.91 (C6), 126.25 (C4), 127.12 (C7), 136.05 (C3b), 143.16 (C3a), 145.89 (C7a), 181.25 (C8a), 191.33 (C3).
Mass spectrum: m/e 217 (10%), 216 (M+, 61), 215(5), 201(15), 189(6), 188(29), 187(20), 183(9), 173(14), 171(6), 158(8), 157(26), 156(14), 155(33), 153(8), 152(7), 142(22), 141(18), 139(14), 130(6), 129(38), 128(19) 127(10), 116(7), 115(38), 114(20), 113(8), 102(7), 89(9), 88(7), 87(9), 86(8), 85(5), 79(9), 77(12), 76(10), 75(10), 74(10), 70(5), 69(5), 65(8), 64(10), 653(27), 62(13), 61(8), 59(100), 51(21), 50(11), 45(14), 41(12), 39(30), all other peaks less than 5%.
Analysis: Found: C, 71.9; H, 5.8, S, 14.9. C13H12OS requires C, 72.2; H, 5.6; S, 14.8%.











DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com








No comments:

Post a comment